Sugi Predict

Sugi Predict / Compounds / SCHEMBL301939

SCHEMBL301939

SCHEMBL301939

C[C@]12CC[C@H](O)CC1=CC(O)[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.66
▸ CA2 P00918 1/20 0.66
▸ CA9 Q16790 1/20 0.66
▸ SHBG P04278 3/20 0.64
▸ CYP3A4 P08684 3/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ SERPINA6 P08185 1/20 0.64
▸ GUSB P08236 1/20 0.64
▸ G6PD P11413 1/20 0.64
▸ PMP22 Q01453 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ GPBAR1 Q8TDU6 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ CYP19A1 P11511 4/20 0.53
▸ GPR183 P32249 6/20 0.51
▸ RORA P35398 2/20 0.51
▸ RORC P51449 2/20 0.51
▸ NPC1L1 Q9UHC9 2/20 0.51
▸ OSBP P22059 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL601163 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL14492219 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL602258 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL14581228 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL14613791 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL10301214 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL1952526 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL14613826 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL2921296 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4
SCHEMBL13753025 1.00 CA1 (0.66) CA1CA2CA9SHBGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118324835-A Method for preparing 7 beta-hydroxy dehydroepiandrosterone by utilizing dehydroepiandrosterone and application 上海格苓凯生物科技有限公司 2024-07-12 — — CN claimed
CN-110755884-B Method for extracting biological product by reverse adsorption 山东睿智医药科技有限公司 2022-01-18 — — CN claimed
JP-4849478-B2 — — 2012-01-11 — — JP claimed
US-20070231373-A1 Transdermal Steriod for Formulation HUNTER-FLEMING LIMITED (UK) 2007-10-04 — — US claimed
EP-1307205-B1 USE OF 7ALPHA-HYDROXY-ESTRADIOL, 7ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE AND 7ALPHA-HYDROXY-PREGNENOLONE DERIVATIVES FOR TREATING ACUTE CELLULAR DEGENERATION UNIV EDINBURGH (GB) 2007-04-04 — — EP claimed
EP-1748779-A1 TRANSDERMAL STEROID FORMULATION Hunter-Fleming Limited (GB) 2007-02-07 — — EP claimed
US-20060264357-A1 Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals ZIKRIA BASHIR A 2006-11-23 — — US claimed
WO-2005105104-A1 TRANSDERMAL STEROID FORMULATION HUNTER-FLEMING LIMITED (GB) 2005-11-10 — — WO claimed
EP-1294381-B1 NEUROPROTECTIVE 7-BETA-HYDROXYSTEROIDS HUNTER FLEMING LTD (GB) 2005-08-31 — — EP claimed
US-6930192-B2 Methods for preparing 7alpha-hydroxy-dehydroepiandrosterone L'OREAL (FR) 2005-08-16 — — US claimed
US-20030092692-A1 Cytoprotective steroids (II) LATHE RICHARD FRANK (GB) 2003-05-15 — — US claimed
EP-1307205-A2 USE OF 7ALPHA-HYDROXY-ESTRADIOL, 7ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE AND 7ALPHA-HYDROXY-PREGNENOLONE DERIVATIVES FOR TREATING ACUTE CELLULAR DEGENERATION BTG INTERNATIONAL LIMITED (GB) 2003-05-07 — — EP claimed
WO-2002064614-A1 METHODS FOR PREPARING 7ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE L'OREAL (FR) 2002-08-22 — — WO claimed
WO-2001060375-A2 USE OF 7ALPHA-HYDROXY-ESTRADIOL, 7ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE AND 7ALPHA-HYDROXY-PREGNENOLONE DERIVATIVES FOR TREATING ACUTE CELLULAR DEGENERATION HUNTER-FLEMING LIMITED (GB) 2001-08-23 — — WO claimed
JP-2000511404-A — — 2000-09-05 — — JP claimed
EP-0954317-A2 USE OF 7 APHA-SUBSTITUTED STEROIDS TO TREAT NEUROPSYCHIATRIC, IMMUNE OR ENDOCRINE DISORDERS BTG INTERNATIONAL LIMITED (GB) 1999-11-10 — — EP claimed
WO-1997037664-A2 USE OF 7 ALPHA-SUBSTITUTED STEROIDS TO TREAT NEUROPSYCHIATRIC, IMMUNE OR ENDOCRINE DISORDERS BRITISH TECHNOLOGY GROUP LTD. (GB) 1997-10-16 — — WO claimed
EP-0547151-A4 TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED -G(D)5-ANDROSTENE — 1993-10-13 — — EP claimed
EP-0547151-A1 TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED $g(D)5-ANDROSTENE HUMANETICS CORPORATION (US) 1993-06-23 — — EP claimed
WO-1992003925-A1 TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5-ANDROSTENE HUMANETICS CORPORATION (US) 1992-03-19 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231373-A1 Transdermal Steriod for Formulation SHBG, HSD17B7, HSD17B3 CA1 2811/4885CA2 3997/4885CA9 4544/4885
US-20030092692-A1 Cytoprotective steroids (II) CYP27A1, CYP27B1, NLN CA1 941/4885CA2 3720/4885CA9 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.